Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
1321 | 2620 | 47.6 | 88% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
412 | 16030 | GENE DELIVERY//GENE THERAPY//POLYETHYLENIMINE |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | ADENO ASSOCIATED VIRUS | Author keyword | 171 | 36% | 15% | 380 |
2 | AAV | Author keyword | 102 | 41% | 7% | 193 |
3 | POWELL GENE THER Y | Address | 47 | 36% | 4% | 106 |
4 | REP78 | Author keyword | 42 | 94% | 1% | 15 |
5 | GENE THER Y | Address | 35 | 11% | 11% | 286 |
6 | ADENO ASSOCIATED VIRUS TYPE 2 | Author keyword | 33 | 100% | 0% | 13 |
7 | CELLULAR MOL THER Y | Address | 29 | 45% | 2% | 49 |
8 | ADENO ASSOCIATED VIRUS AAV | Author keyword | 20 | 52% | 1% | 28 |
9 | AAV VECTORS | Author keyword | 20 | 51% | 1% | 28 |
10 | GENE THER Y PROGRAM | Address | 19 | 19% | 4% | 94 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ADENO ASSOCIATED VIRUS | 171 | 36% | 15% | 380 | Search ADENO+ASSOCIATED+VIRUS | Search ADENO+ASSOCIATED+VIRUS |
2 | AAV | 102 | 41% | 7% | 193 | Search AAV | Search AAV |
3 | REP78 | 42 | 94% | 1% | 15 | Search REP78 | Search REP78 |
4 | ADENO ASSOCIATED VIRUS TYPE 2 | 33 | 100% | 0% | 13 | Search ADENO+ASSOCIATED+VIRUS+TYPE+2 | Search ADENO+ASSOCIATED+VIRUS+TYPE+2 |
5 | ADENO ASSOCIATED VIRUS AAV | 20 | 52% | 1% | 28 | Search ADENO+ASSOCIATED+VIRUS+AAV | Search ADENO+ASSOCIATED+VIRUS+AAV |
6 | AAV VECTORS | 20 | 51% | 1% | 28 | Search AAV+VECTORS | Search AAV+VECTORS |
7 | AAV VECTOR | 15 | 49% | 1% | 22 | Search AAV+VECTOR | Search AAV+VECTOR |
8 | AAV SEROTYPES | 15 | 88% | 0% | 7 | Search AAV+SEROTYPES | Search AAV+SEROTYPES |
9 | AAV5 | 13 | 80% | 0% | 8 | Search AAV5 | Search AAV5 |
10 | RAAV | 12 | 31% | 1% | 31 | Search RAAV | Search RAAV |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | AAV | 194 | 78% | 5% | 128 |
2 | ADENO ASSOCIATED VIRUS | 167 | 62% | 7% | 174 |
3 | ADENOASSOCIATED VIRUS | 157 | 29% | 17% | 452 |
4 | EFFICIENT TRANSDUCTION | 152 | 53% | 8% | 200 |
5 | RECOMBINANT ADENOASSOCIATED VIRUS | 146 | 36% | 12% | 325 |
6 | DETROIT 6 CELLS | 125 | 97% | 1% | 35 |
7 | VIRAL VECTORS | 121 | 29% | 13% | 348 |
8 | AAV VECTORS | 95 | 58% | 4% | 109 |
9 | AAV SEROTYPES | 75 | 74% | 2% | 55 |
10 | LIVER TRANSDUCTION | 73 | 86% | 1% | 37 |
Journals |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | HUMAN GENE THERAPY METHODS | 8 | 24% | 1% | 30 |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Immune responses to AAV vectors: overcoming barriers to successful gene therapy | 2013 | 61 | 132 | 79% |
The AAV Vector Toolkit: Poised at the Clinical Crossroads | 2012 | 81 | 122 | 75% |
Engineering adeno-associated viruses for clinical gene therapy | 2014 | 24 | 69 | 74% |
Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges | 2011 | 210 | 158 | 57% |
Gene Therapy Using Adeno-Associated Virus Vectors | 2008 | 190 | 77 | 94% |
Adeno-associated virus serotypes: Vector toolkit for human gene therapy | 2006 | 292 | 115 | 91% |
New recombinant serotypes of AAV vectors | 2005 | 247 | 38 | 87% |
Directed evolution of novel adeno-associated viruses for therapeutic gene delivery | 2012 | 45 | 57 | 82% |
Adeno-Associated Virus Vectors and Neurological Gene Therapy | 2015 | 4 | 92 | 60% |
ADENO-ASSOCIATED VIRUS VECTOROLOGY, MANUFACTURING, AND CLINICAL APPLICATIONS | 2012 | 41 | 124 | 84% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | POWELL GENE THER Y | 47 | 36% | 4.0% | 106 |
2 | GENE THER Y | 35 | 11% | 11% | 286 |
3 | CELLULAR MOL THER Y | 29 | 45% | 1.9% | 49 |
4 | GENE THER Y PROGRAM | 19 | 19% | 3.6% | 94 |
5 | CELLULAR MOL THER EUT | 19 | 41% | 1.4% | 36 |
6 | EXCELLENCE REGENERAT HLTH BIOTECHNOL | 18 | 89% | 0.3% | 8 |
7 | GENET THER EUT | 14 | 27% | 1.7% | 44 |
8 | UNC GENE THER Y | 12 | 59% | 0.5% | 13 |
9 | U649 | 9 | 55% | 0.5% | 12 |
10 | ABRAMSON 310A | 8 | 100% | 0.2% | 5 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000136583 | ALEUTIAN MINK DISEASE VIRUS//DENSOVIRUS//U375 |
2 | 0.0000125028 | LEBER CONGENITAL AMAUROSIS//RPE65//CNGB3 |
3 | 0.0000112626 | GENE MED GRP//GENEMED GRP//EXPT TREATMENT CYST FIBROSIS |
4 | 0.0000091602 | MOL MED GENE THER Y UNIT//GUTLESS//HELPER DEPENDENT ADENOVIRUS |
5 | 0.0000072768 | W ROXBURY VA HOSP//HERPES SIMPLEX VIRUS VECTOR//HELPER VIRUS FREE PACKAGING |
6 | 0.0000072280 | ORTHOKINE//MOL ORTHOPAED//UNITE RECH IMMUNOPATHOL MALAD TUMORALES AUTOIMM |
7 | 0.0000067526 | SKIN GENE THERAPY//HUMAN CLOTTING FACTOR IX//CLOTTING FACTOR IX |
8 | 0.0000065149 | HYDRODYNAMICS BASED PROCEDURE//HYDRODYNAMICS BASED TRANSFECTION//HYDRODYNAMIC DELIVERY |
9 | 0.0000059513 | INSULIN GENE THERAPY//DIABETES GENE THERAPY//ENDOCRINOL METAB SECT 111 |
10 | 0.0000057998 | LENTIVIRAL VECTOR//LENTIVIRAL VECTORS//EXPT HEMATOL |